Cargando…

Adverse Cardiac Effects of CAR T-Cell Therapy: Characteristics, Surveillance, Management, and Future Research Directions

This review summarizes the current literature on the adverse cardiac effects of CAR T-cell therapy. Case reports and series suggest that major adverse cardiovascular events are not uncommon after CAR T-cell therapy; however, limited data exist regarding incidence, pathophysiology, and prevention str...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dalal, Prarthana J., Patel, Nikita P., Feinstein, Matthew J., Akhter, Nausheen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2022
Materias:	Advances in CAR-T cell Therapies for Cancer
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9580078/ https://www.ncbi.nlm.nih.gov/pubmed/36254553 http://dx.doi.org/10.1177/15330338221132927

Ejemplares similares

Relapse Mechanism and Treatment Strategy After Chimeric Antigen Receptor T-Cell Therapy in Treating B-Cell Hematological Malignancies
por: Xie, Danni, et al.
Publicado: (2022)

How I approach optimization of patients at risk of cardiac and pulmonary complications after CAR T-cell therapy
por: Gutierrez, Cristina, et al.
Publicado: (2023)

How I treat cytopenias after CAR T-cell therapy
por: Jain, Tania, et al.
Publicado: (2023)

How I treat refractory CRS and ICANS after CAR T-cell therapy
por: Jain, Michael D., et al.
Publicado: (2023)

How I treat unique and difficult-to-manage cases of CAR T-cell therapy–associated neurotoxicity
por: Santomasso, Bianca D., et al.
Publicado: (2023)

Some Notes from the Olympia Motor Show
Publicado: (1919)

Filgrastim associations with CAR T‐cell therapy
por: Gaut, Daria, et al.
Publicado: (2020)

Delay in COVID-19 Presentation in Patients Recently Treated with CD-19 Directed CAR-T Therapy
por: Wuliji, Natalie, et al.
Publicado: (2022)

CAR-T-Zell-Therapie beim multiplen Myelom
por: Zhou, X., et al.
Publicado: (2021)

Did COVID-19 Push CAR-T to the Outpatient Setting?
por: Harris, Alyssa, et al.
Publicado: (2022)

Cardiac cell therapy: overexpression of connexin43 in skeletal myoblasts and prevention of ventricular arrhythmias
por: Fernandes, Sarah, et al.
Publicado: (2009)

Allogeneic transplant following CAR T-cell therapy for large B-cell lymphoma
por: Zurko, Joanna, et al.
Publicado: (2022)

Current state and future of photodynamic therapy for the treatment of head and neck squamous cell carcinoma
por: Mimikos, Christina, et al.
Publicado: (2016)

Patient-reported outcomes in CD30-directed CAR-T cells against relapsed/refractory CD30+ lymphomas
por: Tschernia, Nicholas P, et al.
Publicado: (2023)

Patient preferences for active surveillance vs standard surgery after neoadjuvant chemoradiotherapy in oesophageal cancer treatment: The NOSANO‐study
por: Hermus, Merel, et al.
Publicado: (2022)

Utilization of Diaphragm Motion to Predict the Displacement of Liver Tumors for Patients Treated with Carbon ion Radiotherapy
por: Li, Yao, et al.
Publicado: (2023)

Salvage radiotherapy in relapsed/refractory large B-cell lymphoma after failure of CAR T-cell therapy
por: Ababneh, Hazim S., et al.
Publicado: (2023)

Limited efficacy of APRIL CAR in patients with multiple myeloma indicate challenges in the use of natural ligands for CAR T-cell therapy
por: Lee, Lydia, et al.
Publicado: (2023)

Lenalidomide Enhances CAR-T Cell Activity Against Solid Tumor Cells
por: Wang, Zhixiong, et al.
Publicado: (2020)

Response to COVID-19 Vaccination Post-CAR T Therapy in Patients with Non-Hodgkin Lymphoma and Multiple Myeloma
por: Wiedmeier-Nutor, Julia Erin, et al.
Publicado: (2022)

Rapamycin Pretreatment Rescues the Bone Marrow AML Cell Elimination Capacity of CAR-T Cells
por: Nian, Zhigang, et al.
Publicado: (2021)

The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R/R LBCL
por: Rejeski, Kai, et al.
Publicado: (2022)

Conventional four field radiotherapy versus computed tomography-based treatment planning in cancer cervix: A dosimetric study
por: Gulia, Abhishek, et al.
Publicado: (2013)

The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial
por: Heiss, Markus M, et al.
Publicado: (2010)

Humoral response to catumaxomab correlates with clinical outcome: Results of the pivotal phase II/III study in patients with malignant ascites
por: Ott, Marion G, et al.
Publicado: (2012)

Prolonged expression of the γ-H2AX DNA repair biomarker correlates with excess acute and chronic toxicity from radiotherapy treatment
por: Bourton, Emma C, et al.
Publicado: (2011)

A mixture of amino acids and other small molecules present in the serum suppresses the growth of murine and human tumors in vivo
por: Kulcsár, Gyula, et al.
Publicado: (2013)

Mangrove dolabrane‐type of diterpenes tagalsins suppresses tumor growth via ROS‐mediated apoptosis and ATM/ATR–Chk1/Chk2‐regulated cell cycle arrest
por: Neumann, Jennifer, et al.
Publicado: (2015)

Oncolytic effects of parvovirus H-1 in medulloblastoma are associated with repression of master regulators of early neurogenesis
por: Lacroix, Jeannine, et al.
Publicado: (2014)

Regorafenib (BAY 73-4506): Antitumor and antimetastatic activities in preclinical models of colorectal cancer
por: Schmieder, Roberta, et al.
Publicado: (2014)

Triptolide reverses hypoxia-induced epithelial–mesenchymal transition and stem-like features in pancreatic cancer by NF-κB downregulation
por: Liu, Li, et al.
Publicado: (2014)

Sorafenib synergizes with metformin in NSCLC through AMPK pathway activation
por: Groenendijk, Floris H, et al.
Publicado: (2015)

Ketone supplementation decreases tumor cell viability and prolongs survival of mice with metastatic cancer
por: Poff, AM, et al.
Publicado: (2014)

Selective depletion of tumor neovasculature by microbubble destruction with appropriate ultrasound pressure
por: Wang, Junfen, et al.
Publicado: (2015)

Antitumor effect of antitissue factor antibody‐MMAE conjugate in human pancreatic tumor xenografts
por: Koga, Yoshikatsu, et al.
Publicado: (2015)

Antitumor activity of an anti‐CD98 antibody
por: Hayes, Gregory M., et al.
Publicado: (2015)

Bone fracture as a novel immune‐related adverse event with immune checkpoint inhibitors: Case series and large‐scale pharmacovigilance analysis
por: Filippini, Daria Maria, et al.
Publicado: (2021)

NK cells enhance CAR-T cell antitumor efficacy by enhancing immune/tumor cells cluster formation and improving CAR-T cell fitness
por: Bachiller, Mireia, et al.
Publicado: (2021)

Quantification of biological variation in blood‐based therapy – a summary of a meta‐analysis to inform manufacturing in the clinic
por: Thurman‐Newell, J. A., et al.
Publicado: (2015)

Large-scale manufacturing and characterization of CMV-CD19CAR T cells
por: Wang, Xiuli, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_s2n9ahdq4i7uc6lgec1ktqk3eg